|
1.
|
2025/03
|
|
Breast cancer statistics for Japan in 2022: annual report of the national clinical database-breast cancer registry-clinical implications including chemosensitivity of breast cancer with low estrogen receptor expression
|
|
2.
|
2025/02/10
|
|
A prospective cohort study of abemaciclib-induced interstitial lung disease in metastatic breast cancer after chemotherapy
|
|
3.
|
2025/02
|
|
A randomized phase III study evaluating dexamethasone-based mouthwash to prevent chemotherapy-induced stomatitis in patients with breast cancer
|
|
4.
|
2025/01
|
|
Real-world incidence of and risk factors for abemaciclib-induced interstitial lung disease in Japan: a nested case-control study of abemaciclib-induced interstitial lung disease (NOSIDE)
|
|
5.
|
2024/07/09
|
|
The effect of exercise and educational programs for breast cancer patients on the development of breast cancer-related lymphoedema: secondary endpoint from a randomized controlled trial in the Setouchi Breast Project-10
|
|
6.
|
2024/06/18
|
|
Baseline gut microbiota as a predictive marker for the efficacy of neoadjuvant chemotherapy in patients with early breast cancer: a multicenter prospective cohort study in the Setouchi Breast Project-14
|
|
7.
|
2024/06
|
|
Prognostic value of the 21-Gene Breast Recurrence Score® assay for hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer: subanalysis from Japan Breast Cancer Research Group-M07 (FUTURE trial).
|
|
8.
|
2024/04
|
|
Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer.
|
|
9.
|
2024/03/19
|
|
Epithelial-mesenchymal transition in tumor cells is correlated with prognosis, and activated intra-tumor immunity is correlated with chemo-sensitivity in breast cancer patients with a non-pathological complete response to neoadjuvant chemotherapy.
|
|
10.
|
2024/03
|
|
2020 Annual Report of National Clinical Database-Breast Cancer Registry: 10-year mortality of elderly breast cancer patients in Japan.
|
|
11.
|
2024/03
|
|
Pilot trial of an electronic patient-reported outcome monitoring system in patients with metastatic breast cancer undergoing chemotherapy.
|
|
12.
|
2024/03
|
|
Survival trends and patient characteristics between 2004 and 2016 for breast cancer in Japan based on the National Clinical Database-Breast Cancer Registry.
|
|
13.
|
2024/02/21
|
|
Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing
|
|
14.
|
2024/02
|
|
Ectopic Breast Cancer Arising within an Axillary Lymph Node.
|
|
15.
|
2024/02
|
|
Investigating the immunological function of alpha-2-glycoprotein 1, zinc-binding in regulating tumor response in the breast cancer microenvironment.
|
|
16.
|
2024/01
|
|
Annual report of the Japanese Breast Cancer Registry for 2019.
|
|
17.
|
2024/01
|
|
Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer.
|
|
18.
|
2024/01
|
|
Long-Term Physical Activity and Body Composition After Exercise and Educational Programs for Breast Cancer: A Randomized Controlled Trial From the Setouchi Breast Project-10.
|
|
19.
|
2023/11
|
|
An observational study of the impact of immediate breast reconstruction on perioperative inflammatory cytokines.
|
|
20.
|
2023/11
|
|
The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition.
|
|
21.
|
2023/09
|
|
Development and validation of a symptom illustration scale from the patient-reported outcome common terminology criteria for adverse events for patients with breast cancer.
|
|
22.
|
2023/06
|
|
Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial).
|
|
23.
|
2023/06
|
|
Impact of Immediate Breast Reconstruction on Survival of Breast Cancer Patients: A Single-Center Observational Study.
|
|
24.
|
2023/03
|
|
Correction: Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment.
|
|
25.
|
2023/01
|
|
Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment.
|
|
26.
|
2023/01
|
|
Predictive value of immune genomic signatures from breast cancer cohorts containing data for both response to neoadjuvant chemotherapy and prognosis after surgery.
|
|
27.
|
2022/11
|
|
Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy.
|
|
28.
|
2022/10
|
|
Association of change in health-related quality of life and treatment discontinuation in metastatic breast cancer: a post hoc, exploratory analysis of two randomized clinical trials.
|
|
29.
|
2022/08
|
|
Gene Expression Profiling between Patient Groups with High and Low Ki67 Levels after Short-term Preoperative Aromatase Inhibitor Treatment for Breast Cancer
|
|
30.
|
2022/05
|
|
Immunological profiles of the breast cancer microenvironment represented by tumor-infiltrating lymphocytes and PD-L1 expression.
|
|
31.
|
2021/11
|
|
YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development.
|
|
32.
|
2021/10
|
|
A Correlation Analysis Between Metabolism-related Genes and Treatment Response to S-1 as First-line Chemotherapy for Metastatic Breast Cancer: The SELECT BC-EURECA Study.
|
|
33.
|
2021/08
|
|
Differences in Attitudes and Practices of Cancer Pain Management between Medical Oncologists and Palliative Care Physicians
|
|
34.
|
2021/08
|
|
Differences in Attitudes and Practices of Cancer Pain Management between Medical Oncologists and Palliative Care Physicians.
|
|
35.
|
2021/04
|
|
A Multicenter Study of Docetaxel at a Dose of 100 mg/m2 in Japanese Patients with Advanced or Recurrent Breast Cancer.
|
|
36.
|
2021/03
|
|
Relationships of physical and breast cancer phenotypes with three single-nucleotide polymorphisms (rs2046210, rs3757318, and rs3803662) associated with breast cancer risk in Japanese women.
|
|
37.
|
2021/03
|
|
Simultaneous hot and cold thyroid nodules: Which is malignant?
|
|
38.
|
2021/01
|
|
Effect of isoflavones on breast cancer cell development and their impact on breast cancer treatments.
|
|
39.
|
2020/11
|
|
Breast cancer survival among Japanese individuals and US residents of Japanese and other origins: a comparative registry-based study.
|
|
40.
|
2020/10
|
|
Evaluation of Prognosis of Juvenile Differentiated Thyroid Carcinoma.
|
|
41.
|
2020/09
|
|
The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs.
|
|
42.
|
2020/07
|
|
Influences of preoperative metformin on immunological factors in early breast cancer.
|
|
43.
|
2020/07
|
|
NSAS-BC02 substudy of chemotherapy-induced amenorrhea (CIA) in premenopausal patients who received either taxane alone or doxorubicin(A) cyclophosphamide(C) followed by taxane as postoperative chemotherapy.
|
|
44.
|
2020/06
|
|
Biomarkers of neoadjuvant/adjuvant chemotherapy for breast cancer.
|
|
45.
|
2020/04
|
|
Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer.
|
|
46.
|
2020/03
|
|
Influence of breast density on breast cancer risk: a case control study in Japanese women.
|
|
47.
|
2020/01
|
|
Recurring radiation-induced angiosarcoma of the breast that was treated with paclitaxel chemotherapy: a case report.
|
|
48.
|
2020/01
|
|
Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004-2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society.
|
|
49.
|
2019/09
|
|
Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples.
|
|
50.
|
2019/09
|
|
Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
|
|
51.
|
2019/08
|
|
Role of Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer Patients: A Study from the Japanese Breast Cancer Registry.
|
|
52.
|
2018/11
|
|
Comparison of Ki-67 labeling index measurements using digital image analysis and scoring by pathologists.
|
|
53.
|
2018/08
|
|
Hormonal Therapy Resistant Estrogen-receptor Positive Metastatic Breast Cancer Cohort (HORSE-BC) Study : Current Status of Treatment Selection in Japan.
|
|
54.
|
2018/06
|
|
Advance care planning in metastatic breast cancer.
|
|
55.
|
2018/06
|
|
CSF-1/CSF-1R axis is associated with epithelial/mesenchymal hybrid phenotype in epithelial-like inflammatory breast cancer.
|
|
56.
|
2018/04
|
|
Current Multidisciplinary Approach to Fertility Preservation for Breast Cancer Patients.
|
|
57.
|
2018/01
|
|
Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer.
|
|
58.
|
2017/04
|
|
Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers.
|
|
59.
|
2017/03
|
|
Development of a Japanese version of the BREAST-Q and the traditional psychometric test of the mastectomy module for the assessment of HRQOL and patient satisfaction following breast surgery.
|
|
60.
|
2017
|
|
Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status.
|
|
61.
|
2016/12
|
|
Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients.
|
|
62.
|
2016/11
|
|
Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry.
|
|
63.
|
2016/10
|
|
A Phase I Trial of 100 mg/m2 Docetaxel in Patients with Advanced or Recurrent Breast Cancer.
|
|
64.
|
2016/09
|
|
A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer.
|
|
65.
|
2016/08
|
|
A phase 1, dose-finding and pharmacokinetic study of gemcitabine with nab-paclitaxel in patients with metastatic breast cancer.
|
|
66.
|
2016/07
|
|
Diagnostic performance of (18)F-fluorodeoxyglucose PET/CT and bone scintigraphy in breast cancer patients with suspected bone metastasis.
|
|
67.
|
2016/06
|
|
Body mass index and survival after diagnosis of invasive breast cancer: a study based on the Japanese National Clinical Database-Breast Cancer Registry.
|
|
68.
|
2016/05
|
|
Evaluation of aldehyde dehydrogenase 1 and transcription factors in both primary breast cancer and axillary lymph node metastases as a prognostic factor.
|
|
69.
|
2016/04
|
|
Distinct breast cancer characteristics between screen- and self-detected breast cancers recorded in the Japanese Breast Cancer Registry.
|
|
70.
|
2016/04
|
|
Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
|
|
71.
|
2016/01
|
|
Assessment of the Ki67 labeling index: a Japanese validation ring study.
|
|
72.
|
2016/01
|
|
Comprehensive prognostic report of the Japanese Breast Cancer Society Registry in 2004.
|
|
73.
|
2016/01
|
|
Comprehensive prognostic report of the Japanese Breast Cancer Society Registry in 2005.
|
|
74.
|
2016/01
|
|
Comprehensive prognostic report of the Japanese Breast Cancer Society registry in 2006.
|
|
75.
|
2016/01
|
|
Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer.
|
|
76.
|
2015/10
|
|
A model to predict upstaging to invasive carcinoma in patients preoperatively diagnosed with ductal carcinoma in situ of the breast.
|
|
77.
|
2015
|
|
Correlation between 18F-fluorodeoxyglucose Positron Emission Tomography/computed Tomography and Clinicopathological Features in Invasive Ductal Carcinoma of the Breast.
|
|
78.
|
2015
|
|
Neoadjuvant Chemotherapy with or without Concurrent Hormone Therapy in Estrogen Receptor-Positive Breast Cancer: NACED-Randomized Multicenter Phase II Trial.
|
|
79.
|
2014/10
|
|
Prognostic significance of the Ki67 scoring categories in breast cancer subgroups.
|
|
80.
|
2014/05
|
|
TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers.
|
|
81.
|
2014/01
|
|
Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers.
|
|
82.
|
2014
|
|
A case of carcinoma showing thymus-like differentiation with a rapidly lethal course.
|
|
83.
|
2013/12
|
|
Effects of lifestyle and single nucleotide polymorphisms on breast cancer risk: a case-control study in Japanese women.
|
|
84.
|
2013/11
|
|
Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers.
|
|
85.
|
2013/11
|
|
TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase.
|
|
86.
|
2013/09
|
|
Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets.
|
|
87.
|
2013/04
|
|
A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories.
|
|
88.
|
2013/01
|
|
Women prefer adjuvant endocrine therapy to chemotherapy for breast cancer treatment.
|
|
89.
|
2013
|
|
Association between mammographic breast density and lifestyle in Japanese women.
|
|
90.
|
2013
|
|
Bayesian mixture models for assessment of gene differential behaviour and prediction of pCR through the integration of copy number and gene expression data.
|
|
91.
|
2013
|
|
DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes.
|
|
92.
|
2013
|
|
Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.
|
|
93.
|
2012/11
|
|
Microfluidics separation reveals the stem-cell-like deformability of tumor-initiating cells.
|
|
94.
|
2012/08
|
|
Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer.
|
|
95.
|
2012/03
|
|
Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry.
|
|
96.
|
2012/02
|
|
Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer.
|
|
97.
|
2012
|
|
Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer.
|
|
98.
|
2012
|
|
Inflammatory breast cancer: what we know and what we need to learn.
|
|
99.
|
2011/12
|
|
Lack of sufficiently strong informative features limits the potential of gene expression analysis as predictive tool for many clinical classification problems.
|
|
100.
|
2011/11
|
|
First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations.
|
|
101.
|
2011/08
|
|
Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.
|
|
102.
|
2011/04
|
|
Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers.
|
|
103.
|
2011/02
|
|
Breast cancer prognostic markers in the post-genomic era.
|
|
104.
|
2011/02
|
|
Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer.
|
|
105.
|
2011/02
|
|
Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.
|
|
106.
|
2011
|
|
Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures.
|
|
107.
|
2011
|
|
Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer.
|
|
108.
|
2010/11
|
|
Predicting prognosis of breast cancer with gene signatures: are we lost in a sea of data?
|
|
109.
|
2010/11
|
|
Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.
|
|
110.
|
2010/10
|
|
Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.
|
|
111.
|
2010/09
|
|
Laparoscopic tailored Nissen fundoplication.
|
|
112.
|
2008/11
|
|
Preoperative assessment of the risk factors that help to predict the prognosis after living donor liver transplantation.
|
|
113.
|
2008/09
|
|
Effects of prophylactic splenic artery modulation on portal overperfusion and liver regeneration in small-for-size graft.
|
|
114.
|
2008/05
|
|
The impact of donor age on the outcome of adult living donor liver transplantation.
|
|
115.
|
2008/02
|
|
The outcome of living donor liver transplantation with prior spontaneous large portasystemic shunts.
|
|
116.
|
2007/11
|
|
Preoperative proximal splenic artery embolization: a safe and efficacious portal decompression technique that improves the outcome of live donor liver transplantation.
|
|
Display 5 items
|
|
Display all(116)
|
